Skip to main content
Erschienen in: Annals of Hematology 5/2014

01.05.2014 | Original Article

Quality of life more impaired in younger than in older diffuse large B cell lymphoma survivors compared to a normative population: a study from the population-based PROFILES registry

verfasst von: M. W. M. van der Poel, S. Oerlemans, H. C. Schouten, F. Mols, J. F. M. Pruijt, H. Maas, L. V. van de Poll-Franse

Erschienen in: Annals of Hematology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to compare health-related quality of life (HRQOL) between diffuse large B cell lymphoma (DLBCL) survivors of different age categories (18–59/60–75/76–85 years) and to compare their HRQOL with an age- and sex-matched normative population. The population-based Eindhoven Cancer Registry was used to select all patients diagnosed with DLBCL from 1999 to 2010. Patients (n = 363) were invited to complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) questionnaire, and 307 survivors responded (85 %). Data from an age- and sex-matched normative population (n = 596) were used for comparison. DLBCL survivors aged 18–59 years scored better on physical functioning, quality of life, appetite loss and constipation than survivors of 76–85 years old (all p < 0.05). Financial problems more often occurred in survivors aged 18–59 years compared to survivors of 76–85 years old (p < 0.01). Compared to the normative population, DLBCL survivors aged 18–59 years showed worse scores on cognitive and social functioning and on dyspnea and financial problems (p < 0.01, large- and medium-size effects). In survivors of the other age categories, only differences with trivial or small-size effects were found. Although younger DLBCL survivors have better HRQOL than older survivors, the differences found between younger survivors and normative population were the largest. This suggests that having DLBCL has a greater impact on younger than older survivors and that the worse HRQOL observed in older DLBCL survivors in comparison with younger survivors is caused mostly by age itself and not by the disease.
Literatur
3.
Zurück zum Zitat Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242PubMedCrossRef Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242PubMedCrossRef
4.
Zurück zum Zitat Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23(18):4117–4126PubMedCrossRef Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23(18):4117–4126PubMedCrossRef
5.
Zurück zum Zitat van de Schans SA, Wymenga AN, van Spronsen DJ, Schouten HC, Coebergh JW, Janssen-Heijnen ML (2012) Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Ann Oncol 23(5):1280–1286PubMedCrossRef van de Schans SA, Wymenga AN, van Spronsen DJ, Schouten HC, Coebergh JW, Janssen-Heijnen ML (2012) Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Ann Oncol 23(5):1280–1286PubMedCrossRef
6.
Zurück zum Zitat Peters FP, Lalisang RI, Fickers MM, Erdkamp FL, Wils JA, Houben SG et al (2001) Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study. Ann Hematol 80(3):155–159PubMedCrossRef Peters FP, Lalisang RI, Fickers MM, Erdkamp FL, Wils JA, Houben SG et al (2001) Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study. Ann Hematol 80(3):155–159PubMedCrossRef
7.
Zurück zum Zitat Thieblemont C, Grossoeuvre A, Houot R, Broussais-Guillaumont F, Salles G, Traulle C et al (2008) Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 19(4):774–779PubMedCrossRef Thieblemont C, Grossoeuvre A, Houot R, Broussais-Guillaumont F, Salles G, Traulle C et al (2008) Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 19(4):774–779PubMedCrossRef
8.
Zurück zum Zitat Peters FP, Fickers MM, Erdkamp FL, Wals J, Wils JA, Schouten HC (2001) The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates. Ann Hematol 80(7):406–410PubMedCrossRef Peters FP, Fickers MM, Erdkamp FL, Wals J, Wils JA, Schouten HC (2001) The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates. Ann Hematol 80(7):406–410PubMedCrossRef
9.
Zurück zum Zitat Kobayashi Y, Miura K, Hojo A, Hatta Y, Tanaka T, Kurita D et al (2011) Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 137(7):1079–1084PubMedCrossRef Kobayashi Y, Miura K, Hojo A, Hatta Y, Tanaka T, Kurita D et al (2011) Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 137(7):1079–1084PubMedCrossRef
10.
Zurück zum Zitat Heutte N, Haioun C, Feugier P, Coiffier B, Tilly H, Ferme C et al (2011) Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant. Leuk Lymphoma 52(7):1239–1248PubMedCrossRef Heutte N, Haioun C, Feugier P, Coiffier B, Tilly H, Ferme C et al (2011) Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant. Leuk Lymphoma 52(7):1239–1248PubMedCrossRef
11.
Zurück zum Zitat Smith SK, Zimmerman S, Williams CS, Zebrack BJ (2009) Health status and quality of life among non-Hodgkin lymphoma survivors. Cancer 115(14):3312–3323PubMedCentralPubMedCrossRef Smith SK, Zimmerman S, Williams CS, Zebrack BJ (2009) Health status and quality of life among non-Hodgkin lymphoma survivors. Cancer 115(14):3312–3323PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Jerkeman M, Kaasa S, Hjermstad M, Kvaloy S, Cavallin-Stahl E (2001) Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med Oncol 18(1):85–94PubMedCrossRef Jerkeman M, Kaasa S, Hjermstad M, Kvaloy S, Cavallin-Stahl E (2001) Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med Oncol 18(1):85–94PubMedCrossRef
13.
Zurück zum Zitat Merli F, Bertini M, Luminari S, Mozzana R, Berte R, Trottini M et al (2004) Quality of life assessment in elderly patients with aggressive non-Hodgkin's lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. Haematologica 89(8):973–978PubMed Merli F, Bertini M, Luminari S, Mozzana R, Berte R, Trottini M et al (2004) Quality of life assessment in elderly patients with aggressive non-Hodgkin's lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. Haematologica 89(8):973–978PubMed
14.
Zurück zum Zitat Smith SK, Crespi CM, Petersen L, Zimmerman S, Ganz PA (2010) The impact of cancer and quality of life for post-treatment non-Hodgkin lymphoma survivors. Psychooncology 19(12):1259–1267PubMedCentralPubMedCrossRef Smith SK, Crespi CM, Petersen L, Zimmerman S, Ganz PA (2010) The impact of cancer and quality of life for post-treatment non-Hodgkin lymphoma survivors. Psychooncology 19(12):1259–1267PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Mols F, Aaronson NK, Vingerhoets AJ, Coebergh JW, Vreugdenhil G, Lybeert ML et al (2007) Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer 109(8):1659–1667PubMedCrossRef Mols F, Aaronson NK, Vingerhoets AJ, Coebergh JW, Vreugdenhil G, Lybeert ML et al (2007) Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer 109(8):1659–1667PubMedCrossRef
16.
Zurück zum Zitat Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P (2005) Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol 75(2):116–123PubMedCrossRef Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P (2005) Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol 75(2):116–123PubMedCrossRef
17.
Zurück zum Zitat Persson L, Larsson G, Ohlsson O, Hallberg IR (2001) Acute leukaemia or highly malignant lymphoma patients' quality of life over two years: a pilot study. Eur J Cancer Care (Engl) 10(1):36–47CrossRef Persson L, Larsson G, Ohlsson O, Hallberg IR (2001) Acute leukaemia or highly malignant lymphoma patients' quality of life over two years: a pilot study. Eur J Cancer Care (Engl) 10(1):36–47CrossRef
18.
Zurück zum Zitat Geffen DB, Blaustein A, Amir MC, Cohen Y (2003) Post-traumatic stress disorder and quality of life in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma in Israel. Leuk Lymphoma 44(11):1925–1929PubMedCrossRef Geffen DB, Blaustein A, Amir MC, Cohen Y (2003) Post-traumatic stress disorder and quality of life in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma in Israel. Leuk Lymphoma 44(11):1925–1929PubMedCrossRef
19.
Zurück zum Zitat Fritz APC, Jack A et al (2000) International classification of diseases for oncology, 3rd edn. World Health Organisation, Geneva Fritz APC, Jack A et al (2000) International classification of diseases for oncology, 3rd edn. World Health Organisation, Geneva
20.
Zurück zum Zitat van de Poll-Franse LV, Horevoorts N, van Eenbergen M, Denollet J, Roukema JA, Aaronson NK et al (2011) The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 47(14):2188–2194PubMedCrossRef van de Poll-Franse LV, Horevoorts N, van Eenbergen M, Denollet J, Roukema JA, Aaronson NK et al (2011) The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 47(14):2188–2194PubMedCrossRef
21.
Zurück zum Zitat van de Poll-Franse LV, Mols F, Gundy CM, Creutzberg CL, Nout RA, Verdonck-de Leeuw IM et al (2011) Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 47(5):667–675PubMedCrossRef van de Poll-Franse LV, Mols F, Gundy CM, Creutzberg CL, Nout RA, Verdonck-de Leeuw IM et al (2011) Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 47(5):667–675PubMedCrossRef
22.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMedCrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMedCrossRef
23.
Zurück zum Zitat Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN (2003) The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 49(2):156–163PubMedCrossRef Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN (2003) The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 49(2):156–163PubMedCrossRef
24.
Zurück zum Zitat Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29(1):89–96PubMedCrossRef Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29(1):89–96PubMedCrossRef
25.
Zurück zum Zitat Hall AE, Boyes AW, Bowman J, Walsh RA, James EL, Girgis A (2012) Young adult cancer survivors' psychosocial well-being: a cross-sectional study assessing quality of life, unmet needs, and health behaviors. Support Care Cancer 20(6):1333–1341PubMedCrossRef Hall AE, Boyes AW, Bowman J, Walsh RA, James EL, Girgis A (2012) Young adult cancer survivors' psychosocial well-being: a cross-sectional study assessing quality of life, unmet needs, and health behaviors. Support Care Cancer 20(6):1333–1341PubMedCrossRef
26.
Zurück zum Zitat Bifulco G, De Rosa N, Tornesello ML, Piccoli R, Bertrando A, Lavitola G et al (2012) Quality of life, lifestyle behavior and employment experience: a comparison between young and midlife survivors of gynecology early stage cancers. Gynecol Oncol 124(3):444–451PubMedCrossRef Bifulco G, De Rosa N, Tornesello ML, Piccoli R, Bertrando A, Lavitola G et al (2012) Quality of life, lifestyle behavior and employment experience: a comparison between young and midlife survivors of gynecology early stage cancers. Gynecol Oncol 124(3):444–451PubMedCrossRef
27.
Zurück zum Zitat Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14):3348–3356PubMedCrossRef Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14):3348–3356PubMedCrossRef
28.
Zurück zum Zitat Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I et al (2007) Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109(9):1905–1913PubMedCrossRef Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I et al (2007) Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109(9):1905–1913PubMedCrossRef
29.
Zurück zum Zitat Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, Rodenhuis S et al (2002) Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 13(9):1387–1397PubMedCrossRef Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, Rodenhuis S et al (2002) Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 13(9):1387–1397PubMedCrossRef
30.
Zurück zum Zitat Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11):2292–2299PubMedCrossRef Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11):2292–2299PubMedCrossRef
31.
Zurück zum Zitat Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB (2005) Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 104(11):2499–2507PubMedCentralPubMedCrossRef Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB (2005) Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 104(11):2499–2507PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Jensen RE, Arora NK, Bellizzi KM, Rowland JH, Hamilton AS, Aziz NM et al (2013) Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma. Cancer 119(3):672–680PubMedCentralPubMedCrossRef Jensen RE, Arora NK, Bellizzi KM, Rowland JH, Hamilton AS, Aziz NM et al (2013) Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma. Cancer 119(3):672–680PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Zebrack BJ, Yi J, Petersen L, Ganz PA (2008) The impact of cancer and quality of life for long-term survivors. Psychooncology 17(9):891–900PubMedCrossRef Zebrack BJ, Yi J, Petersen L, Ganz PA (2008) The impact of cancer and quality of life for long-term survivors. Psychooncology 17(9):891–900PubMedCrossRef
34.
Zurück zum Zitat Brandt J, Dietrich S, Meissner J, Neben K, Ho AD, Witzens-Harig M (2010) Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy. Leuk Lymphoma 51(11):2012–2020PubMedCrossRef Brandt J, Dietrich S, Meissner J, Neben K, Ho AD, Witzens-Harig M (2010) Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy. Leuk Lymphoma 51(11):2012–2020PubMedCrossRef
35.
Zurück zum Zitat Mols F, Thong MS, Vissers P, Nijsten T, van de Poll-Franse LV (2012) Socio-economic implications of cancer survivorship: results from the PROFILES registry. Eur J Cancer 48(13):2037–2042PubMedCrossRef Mols F, Thong MS, Vissers P, Nijsten T, van de Poll-Franse LV (2012) Socio-economic implications of cancer survivorship: results from the PROFILES registry. Eur J Cancer 48(13):2037–2042PubMedCrossRef
36.
Zurück zum Zitat Mols F, Vingerhoets AJ, Coebergh JW, Vreugdenhil G, Aaronson NK, Lybeert ML et al (2006) Better quality of life among 10–15 year survivors of Hodgkin's lymphoma compared to 5–9 year survivors: a population-based study. Eur J Cancer 42(16):2794–2801PubMedCrossRef Mols F, Vingerhoets AJ, Coebergh JW, Vreugdenhil G, Aaronson NK, Lybeert ML et al (2006) Better quality of life among 10–15 year survivors of Hodgkin's lymphoma compared to 5–9 year survivors: a population-based study. Eur J Cancer 42(16):2794–2801PubMedCrossRef
37.
Zurück zum Zitat Mols F, Thong MS, Vreugdenhil G, van de Poll-Franse LV (2009) Long-term cancer survivors experience work changes after diagnosis: results of a population-based study. Psychooncology 18(12):1252–1260PubMedCrossRef Mols F, Thong MS, Vreugdenhil G, van de Poll-Franse LV (2009) Long-term cancer survivors experience work changes after diagnosis: results of a population-based study. Psychooncology 18(12):1252–1260PubMedCrossRef
38.
Zurück zum Zitat Hasselblom S, Stenson M, Werlenius O, Sender M, Lewerin C, Hansson U et al (2012) Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. Leuk Lymphoma 53(3):394–399PubMedCrossRef Hasselblom S, Stenson M, Werlenius O, Sender M, Lewerin C, Hansson U et al (2012) Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. Leuk Lymphoma 53(3):394–399PubMedCrossRef
39.
Zurück zum Zitat Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 26(19):3159–3165PubMedCrossRef Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 26(19):3159–3165PubMedCrossRef
40.
Zurück zum Zitat Lee L, Crump M, Khor S, Hoch JS, Luo J, Bremner K et al (2012) Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis. Br J Haematol 158(4):481–488PubMedCrossRef Lee L, Crump M, Khor S, Hoch JS, Luo J, Bremner K et al (2012) Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis. Br J Haematol 158(4):481–488PubMedCrossRef
41.
Zurück zum Zitat Lin TL, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH et al (2012) The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol 91(9):1383–1391PubMedCrossRef Lin TL, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH et al (2012) The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol 91(9):1383–1391PubMedCrossRef
42.
Zurück zum Zitat Griffiths RI, Gleeson ML, Mikhael J, Dreyling MH, Danese MD (2012) Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. Cancer 118(24):6079–6088PubMedCrossRef Griffiths RI, Gleeson ML, Mikhael J, Dreyling MH, Danese MD (2012) Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. Cancer 118(24):6079–6088PubMedCrossRef
Metadaten
Titel
Quality of life more impaired in younger than in older diffuse large B cell lymphoma survivors compared to a normative population: a study from the population-based PROFILES registry
verfasst von
M. W. M. van der Poel
S. Oerlemans
H. C. Schouten
F. Mols
J. F. M. Pruijt
H. Maas
L. V. van de Poll-Franse
Publikationsdatum
01.05.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 5/2014
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1980-1

Weitere Artikel der Ausgabe 5/2014

Annals of Hematology 5/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.